AC Immune.
expertise in the understanding and treatment of neurodegeneration
- Reports this week
- 1
- Active events
- 0
- Connections
- 30
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
AC Immune's CEO sold 10,000 shares, and Jefferies Financial Group provided buy ratings and targets for the company.Some support1 report
-
AC Immune announced details regarding ongoing collaborations with Janssen and LILLY, led by CEO Andrea Pfeifer.Some support3 reports
-
The US market provides opportunities for biopharma companies, including AC Immune.Some support1 report
-
Zacks Investment Research downgraded three companies—Alexander's, AC Immune, and AmBev—to Strong Sell on August 6, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around AC Immune this week
News at the entities that move AC Immune most-
Johnson & Johnson StructuralP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves AC Immune
-
Vijay TransactionalVijay's government in Tamil Nadu formulated its first full-scale budget and allocated welfare funds.Moves AC Immune
-
Jefferies Financial Group TransactionalApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves AC Immune
-
Boston StructuralThe Federal Aviation Administration is managing air traffic operations at Boston Logan Airport.Moves AC Immune
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves AC Immune
-
Nasdaq StructuralAppLovin stock is traded on Nasdaq, and both AppLovin and Trade Desk operate in the competitive digital advertising technology landscape.Moves AC Immune
Connections
The 11 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Andrea Pfeifer Structural
Andrea Pfeifer holds the formal role of CEO of AC Immune.
-
Johnson & Johnson Structural
AC Immune collaborates with Johnson & Johnson on drug evaluation, with milestone payments triggered by trial progress.
-
Vijay Transactional
The individual's foundation provides necessary research funding for AC Immune's clinical trials.
-
Nasdaq Structural
AC Immune is a company that operates and trades on the Nasdaq stock exchange.
-
Boston Structural
AC Immune maintains a subsidiary in Boston.
-
Jefferies Financial Group Transactional
Jefferies Financial Group provides buy ratings and price targets for AC Immune.
-
FDA Structural
AC Immune is seeking review from the FDA regarding its Part 2 trial submission.
-
Europe Shared context
AC Immune is conducting Phase 1 clinical trials within the geographical boundaries of Europe.
Show all 11 connections
-
Lausanne Shared context
AC Immune is geographically based and operates within the city of Lausanne.
-
Switzerland Shared context
AC Immune is a company headquartered and operating within Switzerland.
-
London Shared context
AC Immune participated in a conference event held in London.
History
Events by the month they beganAugust 2026
1 eventJune 2026
5 events- AC Immune received research funding for clinical trials on June 11th.
- AC Immune's CEO sold 10,000 shares, and Jefferies Financial Group provided buy ratings and targets for the company.
- AC Immune announced details regarding ongoing collaborations with Janssen and LILLY, led by CEO Andrea Pfeifer.
- The US market provides opportunities for biopharma companies, including AC Immune.
- Zacks Investment Research downgraded three companies—Alexander's, AC Immune, and AmBev—to Strong Sell on August 6, 2025.